TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03885791

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vaginal cryotherapy
Description: Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal cryotherapy
Description: Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application.
Study: NCT01722604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brinzolamide 1% ophthalmic suspension
Description: brinzolamide 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt 1%
Description: Azopt 1%, RLD
Study: NCT02184195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet -100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet-150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match Olaparib 100mg placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Match Olaparib 150mg placebo
Study: NCT01707043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex
Description: Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex
Description: Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
Study: NCT01462435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (lower dose)
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (upper dose)
Description: Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT04689581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided bi-level erector spinae plane block
Description: Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided modified pectoral nerve block
Description: Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
Study: NCT00803699

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily placebo capsules for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: selenium as L-selenomethionine
Description: daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
Study: NCT00871182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT001
Description: single dose, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT001
Description: single dose, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT001
Description: single dose, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT001
Description: single dose, inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: single dose, inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Handihaler
Description: single dose, tiotropium 18 mcg administered via the Handihaler
Study: NCT02385149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole grain wheat
Description: A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat
Description: A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
Study: NCT00545298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide - same dose 6 wks
Description: 200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide modified treatment
Description: 200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
Study: NCT01830751

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Restrained Sitting Treatment
Description: Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrained Sitting Treatment
Description: Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
Study: NCT00333398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free
Description: CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
Description: CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
Description: CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
Description: CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Thimerosal
Description: Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
Study: NCT04140656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plantar sensitive exercises
Description: Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Textured insole
Description: Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)
Study: NCT03339206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constituent message with FDA and quitline
Description: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constituent message without FDA and quitline
Description: Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Littering message (Control)
Description: Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
Study: NCT01087775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Plasticity Based Adaptive Cognitive Remediation (PACR)
Study: NCT02668874

Intervention type: DEVICE
Group type: OTHER
Intervention: Isolite System

Intervention type: OTHER
Group type: OTHER
Intervention: Cotton Roll Technique
Study: NCT01845922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Low sodium diet
Study: NCT03912142

Intervention type: DIAGNOSTIC_TEST
Intervention: three dimensional Transperineal Ultrasound Scan
Description: Diagnostic test: three dimensional transperineal ultrasound scan
Study: NCT00810004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Intravenous infusion of iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject
Description: Intravenous infusion of iron
Study: NCT03542006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide Ophthalmic
Description: Topical brinzolamide given bd for 3 months
Study: NCT03230552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional surgical video
Description: An instructional surgical video shown to residents before they perform LSO surgery.
Study: NCT00454259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl/Placebo injection
Description: Ultra low dose intravenous injection
Study: NCT04146740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Exercise for Experimental (Structured Exercise) Group
Description: Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control treatment for both groups
Description: Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control treatment for both groups
Description: Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
Study: NCT00956397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: rifaximin 550 mg TID PO x 10 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo TID x 10 days
Study: NCT04267419

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary biomarker
Description: MDA and NO as salivary biomarkers
Study: NCT04346589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
Description: Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
Study: NCT00891982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTGel/ BPO Wash
Description: Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soap Free Cleanser and CTGel
Description: Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days.
Study: NCT04424654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Testosterone cypionate 400 mg IM
Study: NCT01617070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Dosed at 20 mg/kg; PO; Phase 3, Phase 4

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Large Neutral Amino Acid Therapy
Description: Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
Study: NCT03707548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPT
Description: BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-triggered bodily interventions
Description: Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone triggered control intervention
Description: The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
Study: NCT02086253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788 and/or BQ-123
Study: NCT02802540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients going to take capsules of placebo until complete 8 weeks.
Study: NCT02850926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer head gear
Description: Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
Study: NCT05462964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifiers Group (İntervention Group 1)
Description: Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pacifier group sweetened with 25% dextrose (İntervention Group 2)
Description: Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
Study: NCT03231046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT-US Fusion Arm
Description: Use of Clear Guide SCENERGY for CBCT-US fusion guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Biopsy or Ablation
Description: Standard of Care
Study: NCT01214928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 50,000 IU po once weekly for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: cholecalciferol 50,000 IU po once weekly for 12 weeks
Study: NCT00595322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bevacizumab and radiation (IMRT)
Description: bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
Study: NCT02777268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Multi-particulate granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Multi-particulate granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Multi-particulate granules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort
Description: Multi-particulate granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Tablet
Study: NCT00839670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light constraint induced therapy
Description: 90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard constraint induced therapy
Description: 360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
Study: NCT03710174

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Infrared LED photobiomodulation
Description: Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED photobiomodulation
Description: The same procedure as LED group with the device turned off.